glp-1 obesity drug news today october 16 2025 Massachusetts cuts coverage for 460K public workers and retirees, jeopardizing care and risking higher long-term health costs. Learn more Harnessing GLP-1 Receptor Agonists for

Glucagon receptor the new third target

What a Doctor May Assess A doctor-led weight management approach may include: Medical consultation Blood tests if needed HbA1c and metabolic health review Weight management treatment options Dose guidance and follow-up Support for side effects and long-term results If you feel like you have been trying to lose weight but your body is not responding, it may be time to understand what is happening medically

NHS access requires meeting NICE criteria: for diabetes when other treatments fail, or for weight management with BMI 35 kg/m plus comorbidities after lifestyle intervention

This patient-centered approach enhances adherence, satisfaction, and outcomes

These models were fitted separately for each of the data sources (ie, CDM, MarketScan, and Medicare) and for each drug comparison (SGLT-2 inhibitors v DPP-4 inhibitors, GLP-1 receptor agonists v DPP-4 inhibitors, and SGLT-2 inhibitors v GLP-1 receptor agonists), for a total of nine propensity score models

Phase 3 trial completion timeline Seven Phase 3 trials are expected to report results during this year